Table 3.
Model 1: The association of inflammatory sNfL level and fGd+ with MRI atrophy and clinical measures at the 10-year follow-up, corrected for age, sex, DMT use, eTIV, BL T2LC and Gd+ LC*
|
|
Mean inflammatory sNfL level | fGd+ | Full model | ||||||||
| MRI/clinical measure | N | B | Std. B | 95% CI | P value† | B | Std. B | 95% CI | P value† | R2 adj. | P value |
| Total GM volume | 25 | −850.8 | −0.399 | −1580.218 to –121.416 | 0.040 | 91 552.9 | 0.362 | 3400.111 to 179 705.771 | 0.065 | 0.504 | <0.001 |
| Total WM volume | 25 | NS | NS | ||||||||
| Total deep GM volume | 25 | −140.31 | −0.556 | −228.417 to −52.198 | 0.010 | NS | 0.341 | 0.004 | |||
| Thalamus volume | 25 | NS | NS | ||||||||
| Mean Cth | 25 | −0.003 | −0.581 | −0.005 to −0.001 | 0.010 | NS | 0.308 | 0.002 | |||
| logLesion volume‡ | 28 | NS | NS | ||||||||
| logLesion count‡ | 28 | 0.004 | 0.498 | 0.001 to 0.007 | 0.018 | NS | 0.220 | 0.007 | |||
| EDSS≥4§ | 31 | NS | NS | ||||||||
| logT25FW‡ | 30 | NS | NS | ||||||||
| logChange in T25FW‡ | 30 | NS | NS | ||||||||
| logD9-HPT‡ | 29 | 0.004 | 0.593 | 0.002 to 0.006 | 0.004 | NS | 0.411 | 0.001 | |||
| logChange in D9-HPT‡ | 29 | NS | NS | ||||||||
| logND9-HPT‡ | 29 | NS | NS | ||||||||
| logChange in ND9-HPT‡ | 29 | −0.006 | −0.498 | −0.010 to −0.001 | 0.024 | NS | 0.399 | 0.002 | |||
| PASAT | 28 | NS | NS | ||||||||
| Change in PASAT | 28 | NS | NS | ||||||||
| Oral SDMT | 28 | NS | NS | ||||||||
*Non-significant covariates removed from final model by backward elimination.
†Adjusted p values after controlling the false discovery rate (FDR) for multiple hypothesis testing.
‡Dependent variable log transformed due to non-normality (log-linear transformation).
§Analysed by logistic regression.
adj, adjusted; B, beta; BL, baseline; Cth, cortical thickness; D9-HPT, dominant hand Nine-Hole Peg Test; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; eTIV, estimated total intracranial volume; fGd+, fraction of MRI scans with new Gadolinium-enhancing lesion; Gd+, gadolinium-enhancing; GM, grey matter; LC, lesion count; ND9-HPT, non-dominant hand Nine-Hole Peg Test; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; sNfL, serum neurofilament light chain; Std, standardised; T25FW, timed 25-foot walk; WM, white matter.